1. Home
  2. GNSS vs RLYB Comparison

GNSS vs RLYB Comparison

Compare GNSS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genasys Inc.

GNSS

Genasys Inc.

HOLD

Current Price

$1.50

Market Cap

77.0M

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$17.02

Market Cap

89.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNSS
RLYB
Founded
1992
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.0M
89.2M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
GNSS
RLYB
Price
$1.50
$17.02
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.75
N/A
AVG Volume (30 Days)
81.8K
7.4K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
44.44
N/A
EPS
N/A
6.16
Revenue
$26,306,790.00
$858,000.00
Revenue This Year
$80.08
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.75
Revenue Growth
29.50
43.00
52 Week Low
$1.40
$0.48
52 Week High
$2.64
$17.57

Technical Indicators

Market Signals
Indicator
GNSS
RLYB
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GNSS
RLYB

About GNSS Genasys Inc.

Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: